Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DRALZINE vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Essential hypertension (off-label),Hypertensive crisis (off-label)
Hypertension
Oral: 50-100 mg twice daily; maximum 200 mg/day.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
Terminal elimination half-life is 2-5 hours in patients with normal renal function; prolonged to 10-20 hours in renal impairment.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Primarily hepatic via N-acetyltransferase (NAT2); exhibits polymorphic acetylation. Metabolites include hydralazine pyruvate hydrazone and other hydrazone derivatives.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal (70-90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <10%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
85-90%, primarily to albumin.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
1.5-2.0 L/kg; indicates extensive tissue distribution, exceeding total body water.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral: 30-50% due to first-pass metabolism.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR 10-50 m L/min: 50 mg twice daily; GFR <10 m L/min: 50 mg once daily.
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg twice daily; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
1-2 mg/kg/day divided every 12 hours; maximum 5 mg/kg/day.
Not established; avoid use in children.
Initiate at 25 mg twice daily; titrate slowly to avoid hypotension.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
None.
None
May induce a lupus-like syndrome, especially in slow acetylators; monitor for symptoms such as arthralgia, fever, and rash.,May cause drug-induced autoimmune hepatitis.,Can precipitate angina or myocardial infarction in patients with coronary artery disease.,Risk of hypotension and reflex tachycardia.
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Hypersensitivity to hydralazine or components,Coronary artery disease (relative contraindication due to risk of myocardial ischemia),Mitral valve rheumatic heart disease (relative),Idiopathic lupus erythematosus
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
DRALZINE should be taken with or without food, but consistent timing is recommended. High-tyramine foods (e.g., aged cheeses, cured meats, fermented products) may increase the risk of hypertensive crisis in patients also taking MAOIs; however, interactions with food are otherwise minimal. Avoid large, high-fat meals as they may affect absorption.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fetal hypotension, adverse fetal heart rate patterns, and neonatal adverse effects (hypotension, tachycardia, fluid retention).
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Compatible with breastfeeding. M/P ratio not established; drug appears in breast milk in low amounts (<1% maternal dose). No reported adverse effects in infants.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
No specific dose adjustments required based on pharmacokinetic changes in pregnancy. However, because of increased blood volume, higher doses may be needed to achieve same antihypertensive effect; titrate to target blood pressure.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
DRALZINE (hydralazine) is a direct-acting vasodilator used primarily for hypertension, especially in pregnancy (pre-eclampsia). It can cause a drug-induced lupus-like syndrome, especially in slow acetylators; monitor for arthralgias, rash, and positive ANA. Tachycardia is a common reflex response; often co-administered with a beta-blocker. Avoid in patients with coronary artery disease, high-output heart failure, or mitral valve rheumatic heart disease.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take exactly as prescribed; do not skip doses or double up.,You may experience dizziness or lightheadedness, especially when standing up; rise slowly and avoid sudden position changes.,Report any joint pain, rash, fever, or chest pain to your healthcare provider immediately.,Avoid alcohol, which can worsen side effects like dizziness and low blood pressure.,Do not stop taking this medication abruptly; sudden withdrawal can cause a rapid increase in blood pressure.
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DRALZINE vs ALDORIL 25, answered by our medical review team.
DRALZINE is a Antihypertensive that works by Dralzine is a direct-acting arteriolar vasodilator that relaxes vascular smooth muscle, leading to decreased systemic vascular resistance and afterload. The exact molecular mechanism is not fully elucidated but involves inhibition of calcium influx and interference with the contractile process.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DRALZINE and ALDORIL 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DRALZINE is: Oral: 50-100 mg twice daily; maximum 200 mg/day.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DRALZINE and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DRALZINE is classified as Category C. First trimester: No evidence of teratogenicity in human studies; however, consider fetal hypotension and impaired uteroplacental perfusion. Second and third trimesters: Risk of fet. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.